Ameliorative effect of SIRT1 in postpartum depression mediated by upregulation of the glucocorticoid receptor

Jia Wang,Si-Fei Ma,Qi Yun,Wen-Jun Liu,Mei-Na Guo,Yong-Qiang Zhu,Zi-Zhong Liu,Jin-Jun Qian,Wei-Ning Zhang
DOI: https://doi.org/10.1016/j.neulet.2021.136112
IF: 3.197
2021-09-01
Neuroscience Letters
Abstract:<p>Recent evidence has confirmed the association of glucocorticoid receptor (GR) gene variants with the "stress" endocrine axis in postpartum depression (PPD). Sirtuin 1 (SIRT1) is an NAD<sup>+</sup>-dependent histone deacetylase and transcriptional enhancer of GR. However, to date, the function of the SIRT1 gene in the regulation of GR expression in PPD remains to be fully determined. A hormone-stimulated pregnancy (HSP) and subsequent "postpartum" withdrawal of estrogen was employed to mimic the fluctuations in estradiol associated with pregnancy and postpartum. We confirmed that estradiol benzoate withdrawal (EW)-rats displayed depression- and anxiety-like behaviors. These behavioral dysfunctions are associated with attenuated expression of SIRT1 and GR in the hippocampus. To assess the role of SIRT1, as well as its regulatory target directly, a selective SIRT1 activator (SRT2104) was infused into the hippocampus of EW-rats. We found that pharmacological activation of hippocampal SIRT1 blocks the development of depression-related, but not anxiety-related, phenotypes of PPD. In addition, the activation of SIRT1 leads to an increase in hippocampal GR expression in EW-rats. We further confirmed that SIRT1 physically interacts with GR in a glucocorticoid-dependent manner. Taken together, our results suggest that neuropathology in PPD is caused, at least in part, by the inhibition of the SIRT1-GR signaling pathway. Elevating SIRT1 levels, either pharmacologically or through other means, could represent a therapeutic strategy for PPD.</p>
neurosciences
What problem does this paper attempt to address?